Logo

Rosetta Genomics to Collaborate with Columbia U. on Lymphoma Biomarkers

Dec 13, 2007
NEW YORK (GenomeWeb News) - Rosetta Genomics will collaborate with Columbia University to develop microRNA-based diagnostic tests for early detection and prognosis of certain types of non-Hodgkin lymphoma and leukemia, Rosetta said today.
 
Under the collaboration, Rosetta Genomics and Columbia researchers will screen for microRNAs that could serve as biomarkers and drug targets for diffuse large cell lymphoma, transformed follicular lymphoma, and chronic lymphocytic leukemia.
 
According to Rosetta Genomics Head of Global R&D Dalia Cohen, 40 percent of DLCL patients respond well to current therapies and have prolonged survival, but researchers do not know why the remainder of patients don’t respond to therapy. "We believe our technology will help answer this question, as well as speed up and simplify the diagnostic process,” Cohen said.
 
The American Cancer Society estimates that around 43,000 people in the US will be diagnosed with these cancers in 2007.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.